vs
Side-by-side financial comparison of 8X8 INC (EGHT) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $185.1M, roughly 1.6× 8X8 INC). Bio-Techne runs the higher net margin — 12.8% vs 2.8%, a 10.1% gap on every dollar of revenue. On growth, 8X8 INC posted the faster year-over-year revenue change (3.4% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 1.6%).
8x8, Inc. is an American provider of cloud communications and customer experience software for businesses. The company offers unified communications, contact center, and communications platform as a service (CPaaS) delivered via a cloud-based architecture. 8x8 is headquartered in Campbell, California. Its common stock trades on the Nasdaq under the ticker symbol EGHT, and the company is led by Samuel Wilson.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
EGHT vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $295.9M |
| Net Profit | $5.1M | $38.0M |
| Gross Margin | 63.9% | 64.6% |
| Operating Margin | 5.2% | 18.4% |
| Net Margin | 2.8% | 12.8% |
| Revenue YoY | 3.4% | -6.4% |
| Net Profit YoY | 68.4% | 68.3% |
| EPS (diluted) | $0.04 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $295.9M | ||
| Q3 25 | $184.1M | — | ||
| Q2 25 | $181.4M | $317.0M | ||
| Q1 25 | $177.0M | $316.2M | ||
| Q4 24 | $178.9M | $297.0M | ||
| Q3 24 | $181.0M | $289.5M | ||
| Q2 24 | $178.1M | $306.1M | ||
| Q1 24 | $179.4M | $303.4M |
| Q4 25 | $5.1M | $38.0M | ||
| Q3 25 | $767.0K | — | ||
| Q2 25 | $-4.3M | $-17.7M | ||
| Q1 25 | $-5.4M | $22.6M | ||
| Q4 24 | $3.0M | $34.9M | ||
| Q3 24 | $-14.5M | $33.6M | ||
| Q2 24 | $-10.3M | $40.6M | ||
| Q1 24 | $-23.6M | $49.1M |
| Q4 25 | 63.9% | 64.6% | ||
| Q3 25 | 64.8% | — | ||
| Q2 25 | 66.4% | 62.7% | ||
| Q1 25 | 67.8% | 67.9% | ||
| Q4 24 | 67.7% | 65.3% | ||
| Q3 24 | 68.1% | 63.2% | ||
| Q2 24 | 67.9% | 66.4% | ||
| Q1 24 | 68.2% | 67.4% |
| Q4 25 | 5.2% | 18.4% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 0.3% | -7.5% | ||
| Q1 25 | 0.2% | 12.2% | ||
| Q4 24 | 5.0% | 16.0% | ||
| Q3 24 | 4.0% | 13.8% | ||
| Q2 24 | -0.8% | 15.0% | ||
| Q1 24 | -7.9% | 22.1% |
| Q4 25 | 2.8% | 12.8% | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | -2.4% | -5.6% | ||
| Q1 25 | -3.1% | 7.1% | ||
| Q4 24 | 1.7% | 11.7% | ||
| Q3 24 | -8.0% | 11.6% | ||
| Q2 24 | -5.8% | 13.3% | ||
| Q1 24 | -13.1% | 16.2% |
| Q4 25 | $0.04 | $0.24 | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $-0.03 | $-0.11 | ||
| Q1 25 | $-0.04 | $0.14 | ||
| Q4 24 | $0.02 | $0.22 | ||
| Q3 24 | $-0.11 | $0.21 | ||
| Q2 24 | $-0.08 | $0.26 | ||
| Q1 24 | $-0.20 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.9M | $172.9M |
| Total DebtLower is stronger | $321.2M | $260.0M |
| Stockholders' EquityBook value | $142.9M | $2.0B |
| Total Assets | $661.5M | $2.5B |
| Debt / EquityLower = less leverage | 2.25× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $86.9M | $172.9M | ||
| Q3 25 | $75.9M | — | ||
| Q2 25 | $81.3M | $162.2M | ||
| Q1 25 | $88.0M | $140.7M | ||
| Q4 24 | $104.2M | $177.5M | ||
| Q3 24 | $117.4M | $187.5M | ||
| Q2 24 | $130.8M | $152.9M | ||
| Q1 24 | $117.3M | $145.3M |
| Q4 25 | $321.2M | $260.0M | ||
| Q3 25 | $325.8M | — | ||
| Q2 25 | $335.4M | $346.0M | ||
| Q1 25 | $350.0M | $330.0M | ||
| Q4 24 | $364.5M | $300.0M | ||
| Q3 24 | $396.9M | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | $409.7M | $389.0M |
| Q4 25 | $142.9M | $2.0B | ||
| Q3 25 | $133.2M | — | ||
| Q2 25 | $128.2M | $1.9B | ||
| Q1 25 | $122.2M | $2.0B | ||
| Q4 24 | $113.0M | $2.1B | ||
| Q3 24 | $109.8M | $2.1B | ||
| Q2 24 | $104.6M | $2.1B | ||
| Q1 24 | $102.0M | $2.0B |
| Q4 25 | $661.5M | $2.5B | ||
| Q3 25 | $670.8M | — | ||
| Q2 25 | $684.3M | $2.6B | ||
| Q1 25 | $683.2M | $2.6B | ||
| Q4 24 | $698.2M | $2.7B | ||
| Q3 24 | $740.1M | $2.7B | ||
| Q2 24 | $755.7M | $2.7B | ||
| Q1 24 | $756.0M | $2.7B |
| Q4 25 | 2.25× | 0.13× | ||
| Q3 25 | 2.45× | — | ||
| Q2 25 | 2.62× | 0.18× | ||
| Q1 25 | 2.86× | 0.16× | ||
| Q4 24 | 3.23× | 0.14× | ||
| Q3 24 | 3.61× | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | 4.02× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.7M | — |
| Free Cash FlowOCF − Capex | $19.1M | — |
| FCF MarginFCF / Revenue | 10.3% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | 4.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.7M | — | ||
| Q3 25 | $8.8M | — | ||
| Q2 25 | $11.9M | $98.2M | ||
| Q1 25 | $5.9M | $41.1M | ||
| Q4 24 | $27.2M | $84.3M | ||
| Q3 24 | $12.3M | $63.9M | ||
| Q2 24 | $18.1M | $75.5M | ||
| Q1 24 | $12.7M | $81.0M |
| Q4 25 | $19.1M | — | ||
| Q3 25 | $7.7M | — | ||
| Q2 25 | $11.5M | $93.3M | ||
| Q1 25 | $5.5M | $31.0M | ||
| Q4 24 | $26.8M | $77.5M | ||
| Q3 24 | $11.1M | $54.7M | ||
| Q2 24 | $17.8M | $57.5M | ||
| Q1 24 | $12.3M | $64.5M |
| Q4 25 | 10.3% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 6.3% | 29.4% | ||
| Q1 25 | 3.1% | 9.8% | ||
| Q4 24 | 15.0% | 26.1% | ||
| Q3 24 | 6.1% | 18.9% | ||
| Q2 24 | 10.0% | 18.8% | ||
| Q1 24 | 6.9% | 21.3% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.2% | 3.2% | ||
| Q4 24 | 0.3% | 2.3% | ||
| Q3 24 | 0.7% | 3.2% | ||
| Q2 24 | 0.2% | 5.9% | ||
| Q1 24 | 0.2% | 5.4% |
| Q4 25 | 4.07× | — | ||
| Q3 25 | 11.52× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | 9.01× | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EGHT
| Services | $179.7M | 97% |
| Other | $5.4M | 3% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
